Inhaltsübersicht

Publikationen

Kirnbauer R, Taub J, Greenstone H, Roden R, Dürst M, Gissmann L, Lowy DR, Schiller JT (1993) Efficient self assembly of human papillomavirus type 16 L1 and L1 plus L2 into virus like particles. J Virol 67, 7203-7210

Kaufmann AM, Gissmann L, Schreckenberger C, Qiao L (1997) Cervical carcinoma cells transfected with the CD80 gene elicit a primary CTL response specific for HPV 16 E7 antigens. Cancer Gene Ther 4:1-6

Jochmus I, Osen W, Altmann A, , Buck G, Hofmann B, Schneider A, Gissmann L, Rammensee H-G (1997) Specificity of human cytotoxic T lymphocytes induced by human papillomavirus type 16 E7 derived peptide. J Gen Virol, 78:1689-1695

Müller M, Zhou J, Reed TD, Rittmüller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L (1997) Chimeric papillomavirus-like particles. Virology 234:93-111

Borchers A, Braspenning J, Meijer J, Gissmann L, Jochmus I (1999). Cytotoxic T cell tolerance in HPV-transgenic mice. Arch Virol, 144:1539-1556

Schäfer K, Müller M, Faath S, Henn A, Osen W, Zentgraf H, Gissmann L, Jochmus I (1999). Immune response to HPV 16 L1/E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. Int J Cancer, 81:881-888.

Jochmus I, Schäfer K, Faath S, Müller M, Gissmann L (1999) Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 30:269-274

Contreras DN, Krammer PH, Potkul RK, Bu P, Rossi, JL, Kaufmann AM, Gissmann L, Qiao, L (2000) Cervical cancer cells induce apoptosis of cytotoxic T cells. J Immunother 23:67-74

Schreckenberger C, Sethupathi P, Kanjanahaluethai A, Müller M, Zhou J, Gissmann L, Qiao L (2000) Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine 19:227-233

Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Müller RT, Jochmus I, Gissmann L, Schneider A, Dürst M (2001) HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 15:285-293

Osen W, Peiler T, Öhlschläger P, Caldeira S, Faath S, Michel N, Müller M, Tommasino M, Jochmus I, Gissmann L (2001) A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19:4276-86

Michel N, Osen W, Gissmann L, Schumacher TN, Müller M (2002). Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination Virology 294:47-59

Öhlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Müller M, Pawlita M, Schäfer K, Sehr P, Staib C, Sutter G, Gissmann L (2003) Human papillomavirus (HPV) type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol, 77:4635-4645

Freyschmidt E.-J, Alonso A, Hartmann G, Gissmann L (2004) Activation of dendritic cells and induction of T cell responses by human papillomavirus type 16 (HPV 16) L1/E7 chimeric virus-like particles is enhanced by CpG ODN or sorbitol. Antiviral Ther, 9:479-489

Steinberg T, Öhlschläger P, Osen W, Gissmann L (2005). Modification of HPV 16 E7 genes: Correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine. 2005 Jan 19;23(9):1149-57

Dell, K, Koesters R, Gissmann L (2006). Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int J Cancer. 2006 Jan 15;118(2):364-72

Dell K, Koesters R, Linnebacher M, Klein C, Gissmann L (2006). Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine. 2006 Mar 20;24(13):2238-47.

Samorski R, Gissmann L, Osen W (2006). Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. Immunol Lett. 2006 Sep 15;107(1):41-9

Dell K, Klein C, Gissmann L (2008). Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Antiviral Therapy 13 (4) (2008) 495-509

Textor S, Duerst M, Jansen L, Accardi R, Tommasino M, Trunk M.J., Porgador A, Watzl C, Gissmann L, Cerwenka A (2008). Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer.
International Journal of Cancer 123 (10) (2008) 2343-2353

Schädlich L, Senger T, Kirschning CJ, Müller M, Gissmann L (2009)
Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
Vaccine. 2009 Mar 4;27(10):1511-22

Senger T, Schädlich L, Gissmann L, Müller M (2009). Enhanced papillomavirus-like particle production in insect cells.
Virology. 2009 Jun 5;388(2):344-53

Schädlich L, Senger T, Gerlach B, Mücke N, Klein C, Bravo IG, Müller M, Gissmann L (2009). Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.
J Virol. 2009 Aug;83(15):7690-705

Patente

Gissmann, L., Müller M, et al. (1995). Papilloma virus-like particles, fusion proteins and process for producing the same. PCT WO 96/11272 (Priority Oct 7, 1994).

Gissmann, L. and Jochmus I (2000). Polypeptid mit immunogenen Funktionen und veränderten biologischen Funktionen des Proteins. Deutsches Patentamt, P 198 19476, (Priority April 4, 1998).

Gissmann, L., Müller, M et al. (2001). Chimäre Virus-ähnliche Partikel bzw. Capsomere von BPV. Deutsches Patentamt 19905883 (Priority Feb 12, 1999).

Müller, M. and Gissmann L (2001). Papillomavirus capsomere vaccine formulations and methods of use. US Patent Office P 98950930.2-2105 (Priority Oct 10, 1997).